FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1198-1200 April 15, 1999 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Morris, M. Related Article by Rose, P. G. Related Article by Keys, H. M. PubMed Citation

Despite screening programs, approximately 14,000 cases of invasive cervical cancer are diagnosed annually in the United States. In approximately half these cases, locally advanced disease is present at the time of diagnosis. In developing countries, the disease is usually advanced by the time of diagnosis, the prevalence is much higher, and cervical cancer is the principal cause of death due to cancer in women.

Pelvic radiation has been the standard, definitive therapy for advanced disease. With this treatment, the overall five-year survival rate is approximately 65 percent, but it ranges from 15 to 80 percent, depending on the extent of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Brizel, D. M., Esclamado, R. (2006). Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum. JCO 24: 2612-2617 [Abstract] [Full Text]  
• Kvols, L. K. (2005). Radiation Sensitizers: A Selective Review of Molecules Targeting DNA and non-DNA Targets. JNM 46: 187S-190S [Abstract] [Full Text]  
• Hedley, D., Pintilie, M., Woo, J., Nicklee, T., Morrison, A., Birle, D., Fyles, A., Milosevic, M., Hill, R. (2004). Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis. Am. J. Pathol. 164: 557-565 [Abstract] [Full Text]  
• Cannistra, S. A., Bast, R. C. Jr., Berek, J. S., Bookman, M. A., Crum, C. P., DePriest, P. D., Garber, J. E., Koh, W.-J., Markman, M., McGuire, W. P. III, Rose, P. G., Rowinsky, E. K., Rustin, G. J.S., Skates, S. J., Vasey, P. A., King, L. (2003). Progress in the Management of Gynecologic Cancer: Consensus Summary Statement. JCO 21: 129s-132 [Full Text]  
• Koh, W.-J. (2003). Controversies in the Radiotherapeutic Management of Cervical Cancer. JCO 21: 218s-223 [Abstract] [Full Text]  
• Sultana, H., Kigawa, J., Kanamori, Y., Itamochi, H., Oishi, T., Sato, S., Kamazawa, S., Ohwada, M., Suzuki, M., Terakawa, N. (2003). Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol 14: 214-219 [Abstract] [Full Text]  
• Fiorica, J. V. (2002). Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan. The Oncologist 7: 36-45 [Abstract] [Full Text]  
• Ghali, W. A., Cornuz, J., McAlister, F. A., Wasserfallen, J.-B., Devereaux, P.J., Naylor, C. D. (2002). Accelerated publication versus usual publication in 2 leading medical journals. CMAJ 166: 1137-1143 [Abstract] [Full Text]  
• Ferrandina, G., Lauriola, L., Distefano, M. G., Zannoni, G. F., Gessi, M., Legge, F., Maggiano, N., Mancuso, S., Capelli, A., Scambia, G., Ranelletti, F. O. (2002). Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients. JCO 20: 973-981 [Abstract] [Full Text]  
• (1999). Concurrent Chemotherapy and Radiotherapy for Advanced Cervical Cancer. JWatch General 1999: 3-3 [Full Text]  
• He, Q., Liang, C. H., Lippard, S. J. (2000). Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA 97: 5768-5772 [Abstract] [Full Text]